Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
ABSTRACT Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Revista de Saúde Pública - 54(2020) |
| Sprache: |
Englisch ; Spanisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Claudia Biguetti [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Chloroquine, toxicity |
|---|
| doi: |
10.11606/s1518-8787.2020054002631 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ012273538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ012273538 | ||
| 003 | DE-627 | ||
| 005 | 20230310042914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.11606/s1518-8787.2020054002631 |2 doi | |
| 035 | |a (DE-627)DOAJ012273538 | ||
| 035 | |a (DE-599)DOAJ0912f05274864f39a25b83b6e088058c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa |a por | ||
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Claudia Biguetti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use. | ||
| 650 | 4 | |a Coronavirus Infections | |
| 650 | 4 | |a Chloroquine, toxicity | |
| 650 | 4 | |a Hydroxychloroquine, toxicity | |
| 650 | 4 | |a Contraindications, Drug | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Mauro Toledo Marrelli |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Brotto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista de Saúde Pública |d Universidade de São Paulo, 2004 |g 54(2020) |w (DE-627)DOAJ000074365 |x 15188787 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |
| 856 | 4 | 0 | |u https://doi.org/10.11606/s1518-8787.2020054002631 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0912f05274864f39a25b83b6e088058c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102020000100606&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1518-8787 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 | ||